NEWARK,
Del., Sept. 29, 2024 /PRNewswire/ -- SeromYx
Systems, a cutting-edge immunology technology company, and
ACROBiosystems, an innovative provider for life science solutions
and tools, are excited to announce the release of their joint study
on the comprehensive functional profiling of approved anti-CD20
monoclonal antibodies (mAbs). The collaboration leverages SeromYx's
advanced biophysical and cellular Fc-effector function platform and
ACROBiosystems' recombinant human full-length CD20 virus-like
particles (VLPs) to provide new insights into the potential drivers
of therapeutic safety and efficacy of anti-CD20 mAbs.
CD20, a critical target for treating B-cell malignancies and
autoimmune diseases, is selectively expressed on B-cells, allowing
for effective B-cell depletion while preserving long-term immune
memory. The study compared the biophysical binding and immune
effector functions of Rituximab (RTX), Ofatumumab (OFA), and
Obinutuzumab (OBZ), providing a detailed analysis of their
mechanisms of action.
"This study not only reinforces the importance of comprehensive
Fc effector profiling as a critical tool for all mAbs in
development, ensuring a deeper understanding of safety and efficacy
mechanisms, but also has implications for the development of new
anti-CD20 mAbs," says Lenny Moise,
VP of Research, at SeromYx.
Robust binding profiles and distinct Fc-effector functions of
the anti-CD20 mAbs were observed throughout the study. Notably, the
collaboration discovered new Fc-effector functions, including
antibody-dependent neutrophil and eosinophil phagocytosis
activities. These findings broaden the understanding of how these
mAbs engage with immune cells, potentially influencing their
efficacy in various clinical settings. "This collaborative study
together with SeromYx represents a significant step in exploring
the expansive applications of our human CD20 full-length VLP. We
are excited to see how our full-length transmembrane proteins
contribute to a greater understanding of antibody drug efficacy,
driving forward innovations in the field of immunology and more,"
stated John Miao, Senior VP at
ACROBiosystems.
About SeromYx Systems
SeromYx Systems leverages high-throughput cell and bead-based
assays, coupled with machine learning computational analysis, to
advance the design and development of therapeutic monoclonal
antibodies. By profiling the functional interactions between
antibodies and innate immune cells, the company enables
biotechnology and pharmaceutical companies to develop targeted
therapies with precision. SeromYx Systems' platform provides one of
the most comprehensive Fc effector function profiling to help
identify antibody functions for targeting pathogens, infected
cells, or tumors.
SeromYx Systems offers an extensive suite of biophysical and
functional assays to support the entire lifecycle of monoclonal
antibody development, from candidate selection to IND and CMC
filing. With a GCLP-certified platform and robust data
interpretation, SeromYx Systems is a trusted partner in the
development of monoclonal therapies that address critical health
challenges and unmet medical needs.
About ACROBiosystems
ACROBiosystems is a subsidiary of ACROBiosystems Group
(SZ.301080), which is a biotechnology company aimed at being a
cornerstone of the global biopharmaceutical and health industries
by providing products and business models innovation. The company
spans across the globe and has established numerous long-term and
stable partnerships with the world's top pharmaceutical enterprises
and numerous well-known academic institutes. The company comprises
several subsidiaries such as ACROBiosystems,
bioSeedin, Condense Capital, and
ACRODiagnostics.
ACROBiosystems is dedicated to helping overcome challenges with
innovative tools and solutions from discovery to the clinic. By
consistently adapting to new regulatory challenges and guidelines,
the company delivers solutions, whether comes through recombinant
proteins, antibodies, assay kits, GMP-grade reagents, or custom
services. ACROBiosystems empowers scientists and engineers
dedicated to innovation to simplify and accelerate the development
of new, better, and more affordable medicines.
Press Contact:
SeromYx Systems
Abigail Harris
Business Development Manager
Abigail.Harris@Seromyx.com
ACROBiosystems
Peter Hsueh
Marketing Product Manager
Peter.Hsueh@acrobiosystems.com
View original
content:https://www.prnewswire.com/news-releases/seromyx-systems-and-acrobiosystems-announce-strategic-collaboration-on-comprehensive-functional-profiling-of-anti-cd20-monoclonal-antibodies-302261806.html
SOURCE ACROBiosystems Group